기준가
$111.44
운용 규모
$941.8M
보수율
-
배당수익률
1.95%
베타
0.44
통화
USD
| YTD | 1개월 | 3개월 | 1년 | 3년 | 5년 |
|---|---|---|---|---|---|
| +7.97% | +5.33% | +7.83% | +26.48% | +15.14% | +10.74% |
| 순위 | 종목코드 | 종목명 | 비중 |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 22.34% |
| 2 | NVS | Novartis AG ADR | 10.53% |
| 3 | MRK | Merck & Co Inc | 9.51% |
| 4 | NVO | Novo Nordisk AS ADR | 5.93% |
| 5 | PFE | Pfizer Inc | 4.85% |
| 6 | BMY | Bristol-Myers Squibb Co | 4.34% |
| 7 | SNY | Sanofi SA ADR | 4.26% |
| 8 | GSK | GSK PLC ADR | 4.17% |
| 9 | AZN.L | AstraZeneca PLC | 4.12% |
| 10 | ABBV | AbbVie Inc | 4.10% |
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
설정일: 2011-12-20